Adagio Therapeutics Inc., of Waltham, Mass., appointed Eric Kimble chief commercial officer and Ed Campanaro senior vice president of clinical operations.
Agios Pharmaceuticals Inc., of Cambridge, Mass., appointed Jonathan Biller chief financial officer, head of legal and corporate affairs, effective Sept. 11.
Allovir Inc., of Cambridge, Mass., appointed Ercem Atillasoy chief regulatory and safety officer.
Anika Therapeutics Inc., of Bedford, Mass., appointed John B. Henneman III and Stephen Richard to its board. Henneman will serve on the compensation and governance and nominating committees. Richard will serve on the audit committee.
Atbtherapeutics, of Aye, Belgium, appointed Werner Cautreels and Vincent Brichard to its board.
Black Diamond Therapeutics Inc., of Cambridge, Mass., appointed Rachel Humphrey chief medical officer and Karsten Witt senior vice president, non-clinical development.
Cognition Therapeutics Inc., of Pittsburgh, appointed Jack A. Khattar to its board.
DBV Technologies SA, of Montrouge, France, appointed Sébastien Robitaille chief financial officer, effective Oct. 2.
Diffusion Pharmaceuticals Inc., of Charlottesville, Va., appointed Robert J. Cobuzzi Jr. president and CEO.
Discgenics Inc., of Salt Lake City, appointed Jeff Poole chief financial officer.
Eli Lilly and Co., of Indianapolis, appointed Patrik Jonsson senior vice president, president of Lilly USA and chief customer officer. Ilya Yuffa was named senior vice president and president of Lilly Bio-Medicines.
Forma Therapeutics Holdings Inc., of Watertown, Mass., appointed Thomas G. Wiggans to its board.
Kymera Therapeutics Inc., of Watertown, Mass., appointed Pamela Esposito and Jeff Albers to its board.
Maxcyte Inc., of Gaithersburg, Md., appointed Amanda L. Murphy chief financial officer and Ron Holtz senior vice president and chief accounting officer.
Recode Therapeutics Inc., of Menlo Park, Calif. and Dallas, appointed Mukul Agarwal chief business officer, Vladimir G. Kharitonov senior vice president, chemistry, manufacturing and controls and Brandon A. Wustman senior vice president, research and development.
Starton Therapeutics Inc., of New York, appointed Kenneth Anderson and Asher Chanan-Khan to its board.